RxDoctor Payments Data

Siddharth Dave, DO

Internal Medicine · Missouri City, TXNPI 1518042035

Payments from drug & device makers

$1,489in general payments, 2019–2025

Across 72 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$350
  • Novo Nordisk$198
  • GSK$179
  • Lilly USA, LLC$173
  • Johnson & Johnson$134
  • AstraZeneca$90
  • plus $366 from 10 others

What the payments were for

  • Food & beverage$1,45798%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,489 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$40,588
Medicare patients
94
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$63,038
JardianceEmpagliflozin48$56,844
EliquisApixaban43$32,453
JanuviaSitagliptin Phosphate21$31,619
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$29,005
Trijardy XrEmpaglifloz/Linaglip/Metformin30$27,665
Tresiba Flextouch U-100Insulin Degludec47$24,957
FarxigaDapagliflozin Propanediol27$23,445
TrulicityDulaglutide13$21,577
MounjaroTirzepatide16$20,361
XareltoRivaroxaban18$19,549
Tresiba Flextouch U-200Insulin Degludec13$10,103
LinzessLinaclotide11$9,829
Repatha SureclickEvolocumab12$9,073
Rosuvastatin Calcium370$9,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr$53$84,50978 claims
Novo NordiskOzempic$198$63,03848 claims
Lilly USA, LLCTrulicity, Mounjaro$173$41,93829 claims
GSKTrelegy Ellipta, Shingrix$179$36,76871 claims
PfizerEliquis$19$32,45343 claims
AstraZenecaFarxiga$90$23,44527 claims
Johnson & JohnsonXarelto$134$19,54918 claims
AbbVieLinzess, Synthroid$17$11,28846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Missouri City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →